KYTHERA BIOPHARMACEUTICALS INC (KYTH) [Rocket]

In millions, except per share items	Dec-31-14	Dec-31-13	Dec-31-12	Dec-31-11	Dec-31-10	Dec-31-09
	10-K	10-K	10-K	10-K	10-K/A	S-1/A
Operating activities
Net loss	-135.6	-51.9	-36.8	-11.2	-16.0

Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount and issuance cost	0.9	0.3	0.3
Non-cash in-process research and development	53.0
Stock-based compensation	12.4	6.5	1.9	0.9	1.0
Changes in assets and liabilities:
Prepaid expenses and other current assets	-0.1	-0.2	0.6	-0.8	-0.2
Restricted cash	5.1	10.9	-8.6	14.4	-21.8
Other assets	-0.4		0.0	0.0
Accounts payable and other accrued liabilities	4.6	0.7	3.2	0.1	2.9
Deferred development funds	-2.1	-12.0	9.2	-14.7	19.6
Other liabilities	1.3	0.0	0.0
Net cash used in operating activities	-59.5	-44.9	-32.7	-22.7	1.9

Investing activities
Purchases of marketable securities	-63.5	-63.8				-34,645.0
Proceeds from sales of marketable securities	47.3	7.4			12.7	31,058.0
Proceeds from maturities of marketable securities	47.3	7.4			12.7	31,058.0
Investment in property and equipment	-2.1	0.0	-0.2	-0.7	-0.1
Net cash (used in) provided by investing activities	-18.3	-56.5	-0.2	-0.7	12.6

Financing activities
Repayment of notes payable	-5.9	-2.8
Net cash (used in) provided by financing activities	-4.5	133.6	77.6	36.3	0.1

Repayment on credit facility
Net (decrease) increase in cash and cash equivalents	-82.3	32.2	44.7	12.9	14.6
Cash and cash equivalents at beginning of period	111.5	79.3	34.6	21,676.0
Cash and cash equivalents at end of period	29.2	111.5	79.3	34.6	21,676.0

Supplemental disclosures
Note payable issued to Bayer at fair value	21.6
Interest expense paid in cash	0.8	1.3	0.1